Germline mutations in the p53 tumour-suppressor gene were initially reported in five families with the Li-Fraumeni syndrome (LFS) (Malkin et al., 1990) . The principal components of LFS include bone and soft-tissue sarcoma in children and young adults and premenopausal breast cancer. Brain tumours, acute leukaemia and adrenocortical carcinoma also occur to excess in these families (Birch et al., 1990; Garber et al., 1991) . Subsequent reports of other LFS families with germline p53 mutations supported the initial conclusion that such mutations formed the genetic basis of cancer predisposition in families with this syndrome (Srivastava et al., 1990; Law et al., 1991; Toguchida et al., 1992) . However, more recent data suggest that coding mutations in the p53 gene occur in only approximately 50% of families with LFS (Brugieres et al., 1993; Birch et al., 1994) . Barnes et al. (1992) have reported a family with features suggestive of LFS, in whom no constitutional mutation in the p53 gene could be detected, but in whom abnormally high levels of wild-type p53 protein in normal cells of affected family members were found. The authors suggested that in this family a germline mutation outside the p53 coding region was affecting expression of p53 protein, and that this resulted in an enhanced cancer risk.
We have previously reported a family with LFS in whom there was a lack of shared alleles for a polymorphism in p53 in a pair of affected sibs (Santibaniez-Koref et al., 1991) . We have now obtained a more detailed pedigree, extended the data on linkage to p53 and have investigated the expression of p53 protein in members of this family. We have also examined the possibility of linkage to candidate loci other than p53.
Materials and methods
The family was ascertained through a female proband who was diagnosed with a myxoid liposarcoma at the age of 30 Figure 1 . DNA was extracted from blood or fixed tissue from affected and unaffected members of the family indicated in Figure 1 . The entire coding sequence of the p53 gene had been analysed in the sample from the proband, using standard procedures and oligonucleotide primers as previously reported (Birch et al., 1994) .
Formalin-fixed tumour and normal tissue was available from persons 97, 99, 163, 174 and tumour only from 221 ( Figure 1) . Expression of p53 protein in tissue sections from these individuals was assessed by immunohistochemical analysis using the rabbit polyclonal p53 antibody CM 1 (Bafrtek et al., 1991; Midgley et al., 1992 (Easton et al., 1993) , three markers within the p53 gene (Harris et al., 1986; Futreal et al., 1991; Jones et al., 1992) , a polymorphic marker within the RB1 gene (McGee et al., 1990) and two markers within The MDM2 gene on chromosome 12q (Heighway et al., 1994) . Primers used to amplify polymorphisms within the MDM2 gene are as follows. The positions are detailed in Figure 2 and the sequences is written 5' to 3'. . A 100 ng aliquot of chromosomal DNA was used as starting material. An initial denaturation step at 96°C for 2 min was followed by 30 cycles of 57°C for 1 min, 74C for 2 min and 96°C for 1 min.
A final cycle of 57°C for 1 min and 74°C for 4 min completed the PCR reaction. PCR products were restricted with NlaIV (NEB) and visualised on 2-2.5% agarose gels (Seakem GTG).
Typing of other microsatellite markers was carried out as previously described (Teare et al., 1993) . Southern analysis of RSaI-digested genomic DNA as described by Heighway et al. (1986) was used to type a marker at D17S34 on chromosome 17p (Kondoleon et al., 1987) .
In the linkage calculations we have assumed a dominant model with gene frequency 0.0001 as found by Lustbader et al. (1992) . LOD scores were calculated using the LINKAGE programme. A LOD score of 3 is considered to be significant evidence of linkage. Negative LOD scores (less than -2) enable linkage to be excluded. (Momand et al., 1992; Oliner et al., 1992) . Furthermore, a recent study by Leach et al. (1993) has suggested that amplification of MDM2 and mutation of p53 may be mutually exclusive events in this type of malignancy. This idea has been supported in the analysis of MDM2 amplification/p53 mutation in human gliomas (Reifenberger et al., 1993) . maximum LOD score 1.47 was found at 0 = 0.16. These results excluded MDM2 as a candidate but suggested the possible presence of a gene on chromosome 12q at a distance from MDM2. Therefore the family was typed for additional markers on chromosome 12q flanking the MDM2 gene. Results for these markers, however, did not support linkage to a gene adjacent to MDM2.
Discussion
Wild-type p53 protein has a short half-life of a few minutes and is not detectable immunohistochemically. Mutant proteins in general have a much longer half-life, typically several hours. This results in accumulation of the protein which can then be detected by immunohistochemistry (Lane & Benchimol, 1990 ). Nuclear staining with p53 antibody is frequently seen in tumour tissue, and often there is a correlation between staining and the presence of a p53 mutation, although false positives and false negatives have also been seen (Bartek et al., 1991; Andersen et al., 1993) . In the present family no mutation was found in the coding sequence of p53, and negative LOD scores were obtained in an analysis of linkage to three polymorphic markers within p53. The direct involvement of the p53 gene in the segregation of cancer susceptibility in this family can therefore be rejected. This is the first example of a LFS family in whom direct involvement of p53 has been excluded by linkage. Other candidate loci have therefore been examined by linkage analysis. Results of the initial linkage analyses effectively excluded RbH and BRCA1. This result, together with the results for p53 and D17S34, cover a large part of chromosome 17.
Positive staining with p53 antibody, however, which affected nearly every cell, was seen in normal tissue as well as tumour tissue in four affected family members. CMI antibody is highly specific, and the presence of positively stained cells in normal tissue is extremely rare Midgley et al., 1992) . We have observed positive staining in normal tissues in individuals with certain germline mutations in the p53 gene. In these patients, however, when compared with the present family there was a much more heterogeneous pattern of staining, with variation in the frequency and intensity (A.M. Kelsey et al., in preparation In the absence of a p53 mutation in the present family the increased expression must be assumed to be wild-type p53 protein. Therefore, another constitutional lesion which interacts with p53 and which confers a familial cancer phenotype consistent with LFS must be present in these individuals. This lesion may be acting to stabilise normal p53 protein, resulting in high levels detectable by immunohistochemistry. Alternatively, it may be that increased levels of p53 protein are being produced to compensate for a defect which is pushing the cell to proliferate, thereby acting as a brake on proliferation. The pattern of cancers and the presence of this unusual immunostaining phenotype in four affected family members clearly indicate that this trait is dominant. Furthermore, we have recently obtained skin biopsies from a number of family members and their spouses. The biopsies from two affected family members showed positive staining with CM1 anibody, but all the spouse control biopsies were negative.
Because the MDM2 oncogene product binds to the p53 protein and can overcome the suppression of transformed cell growth exerted by wild-type p53, we considered MDM2 to be a good candidate in this family, but linkage analysis to two intragenic MDM2 markers yielded a highly negative LOD score at zero recombination, thereby excluding MDM2. Although positive LOD scores were obtained at a recombination distance from MDM2, analysis of further markers on chromosome 12q did not support linkage to this region. Therefore this small positive LOD score can be assumed to be spurious.
There are many similarities between our family and the family described by Barnes et al. (1992) The majority of germline p53 mutations found in LFS families are missense mutations, resulting in an altered protein product, many of which appear to show a gain of function (Dittmer et al., 1993; Birch et al., 1994) . It may be, therefore, that, although the type of cancers seen in families in which another gene effectively negates normal p53 are similar to those found in families with germline mutations in the p53 gene, a less highly penetrant cancer phenotype results in these families in terms of age of onset of cancers, compared with those families with germline gain-of-function mutations in the p53 gene itself. In carriers of germline p53 mutations loss of the wild-type p53 allele would be required for full loss of normal p53 function. If it is assumed that the inherited trait in the present family results in constitutional loss of p53 function, then the higher penetrance in the families with germline missense mutations may provide additional support for the notion of gain of function in such mutations. Alternatively, the relatively mild phenotype in the present family associated with high constitutional levels of wild-type p53 may indicate that in this family the p53 produced retains at least partial function.
Although Li-Fraumeni families are rare, breast cancer is one of the principal component cancers in families with this syndrome. It is possible therefore that the gene responsible for cancer predisposition in this family will be important in the histogenesis of breast cancer in general, and may be involved in at least a proportion of familial breast cancer not accounted for by the BRCAJ gene. We are therefore continuing our studies to locate the responsible gene in this highly informative family.
